CLINICAL_TRIALS
trial_result
· 2021-10-28
Clinical Trial Update: A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients [Phase 3]
Summary
Phase 3 safety evaluation trial of TEV-48125 self-administered for migraine completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-10-28